Evidence map›Paper›PMID 42558163›Full record

ReviewFrontiers in oncology2026

Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.

Gabriele Ricciardi, Vincenzo Fiorentino, Pietro Tralongo, Maria Lentini, Ludovica Pepe, Valeria Zuccalà, Mariagiovanna Ballato, Giuseppe Giuffrè, Antonio Ieni, Biagio Zampogna and 3 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gabriele Ricciardi *BIOMORF Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, A.O.U. Policlinico "G.Martino"- Via Consolare Valeria 1, Messina, Italy.
Vincenzo Fiorentino *BIOMORF Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, A.O.U. Policlinico "G.Martino"- Via Consolare Valeria 1, Messina, Italy.
Pietro TralongoBIOMORF Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, A.O.U. Policlinico "G.Martino"- Via Consolare Valeria 1, Messina, Italy.
Maria LentiniDepartment of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy.
Ludovica PepeBIOMORF Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, A.O.U. Policlinico "G.Martino"- Via Consolare Valeria 1, Messina, Italy.
Valeria ZuccalàDepartment of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy.
Mariagiovanna BallatoBIOMORF Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, A.O.U. Policlinico "G.Martino"- Via Consolare Valeria 1, Messina, Italy.
Giuseppe GiuffrèDepartment of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy.
Antonio IeniDepartment of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy.
Biagio ZampognaBIOMORF Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, Section of Orthopaedic and Trauma Surgery, A.O.U. Policlinico "G.Martino", University of Messina, Messina, Italy.
Marco FerlazzoIstituto Clinico Polispecialistico C.O.T. Cure Ortopediche Traumatologiche s.p.a., Messina, Italy.
Guido FaddaDepartment of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy.
Maurizio MartiniDepartment of Human Pathology of Adults and Developmental Age "Gaetano Barresi," Division of Pathology, University of Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is an aggressive primary bone malignancy characterized by high metastatic potential and limited therapeutic progress. Beyond genomic instability, accumulating evidence indicates that OS operates as a communication-driven disease in which dynamic intercellular signaling networks within the tumor microenvironment regulate tumor growth, immune evasion, metastatic dissemination, and therapy resistance. This review integrates current knowledge on immune cell crosstalk, extracellular vesicle-mediated signaling, soluble factors, and direct cell-cell interactions that coordinate local and systemic tumor progression. We discuss how these interconnected communication circuits shape the tumor immune microenvironment and sustain adaptive plasticity. Finally, we highlight emerging strategies aimed at disrupting pathological signaling networks, while acknowledging that many communication-targeted approaches remain at the preclinical stage or require further clinical validation. Framing OS as a communication-driven ecosystem provides a unifying conceptual model to identify novel therapeutic vulnerabilities.

Indexed as

extracellular vesiclesimmunotherapyintercellular communicationosteosarcomatumor microenvironment

Identifiers

PMID42558163
PMCPMC13437353

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.